Literature DB >> 7699995

Proteolytic processing of human prorenin in renal and non-renal tissues.

T L Reudelhuber1, D Ramla, L Chiu, C Mercure, N G Seidah.   

Abstract

Previous studies have demonstrated that the mouse proprotein convertase PC1 (mPC1) accurately cleaves human prorenin to generate active renin and that this processing event appears to require co-packaging in secretory granules. In the current study, we have tested human PC1 (hPC1; also called PC3) for its ability to activate human prorenin. Our results suggest that while hPC1 is capable of carrying out the specific cleavage of human prorenin, it does so at a reduced efficiency as compared to mPC1. This difference is due to sequences in the carboxy-terminus of PC1 as demonstrated by the activity of hybrid hPC1/mPC1 molecules. These studies demonstrate that PC1 cleavage of prorenin can occur in humans and identify a functionally important region in the hPC1 protein for this interaction. Moreover, the localization of PC1 in human tissues suggests that it may participate in the generation of active renin in the adrenal medulla and possibly in certain adrenal tumors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7699995     DOI: 10.1038/ki.1994.435

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  12 in total

1.  Renin and cardiovascular disease: Worn-out path, or new direction.

Authors:  Gaurav Alreja; Jacob Joseph
Journal:  World J Cardiol       Date:  2011-03-26

2.  Structural libraries of protein models for multiple species to understand evolution of the renin-angiotensin system.

Authors:  Jeremy W Prokop; Victoria Petri; Mary E Shimoyama; Ingrid K M Watanabe; Dulce E Casarini; Thomas C Leeper; Stephanie M Bilinovich; Howard J Jacob; Robson A S Santos; Almir S Martins; Fabiano C Araujo; Fernando M Reis; Amy Milsted
Journal:  Gen Comp Endocrinol       Date:  2014-09-26       Impact factor: 2.822

3.  Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver.

Authors:  M Véniant; J Ménard; P Bruneval; S Morley; M F Gonzales; J Mullins
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

Review 4.  The proprotein convertases are potential targets in the treatment of dyslipidemia.

Authors:  Nabil G Seidah; Annik Prat
Journal:  J Mol Med (Berl)       Date:  2007-03-10       Impact factor: 4.599

5.  Evaluation of Active Renin Concentration in A Cohort of Adolescents with Primary Hypertension.

Authors:  Anna Deja; Piotr Skrzypczyk; Magdalena Nowak; Małgorzata Wrońska; Michał Szyszka; Anna Ofiara; Justyna Lesiak-Kosmatka; Anna Stelmaszczyk-Emmel; Małgorzata Pańczyk-Tomaszewska
Journal:  Int J Environ Res Public Health       Date:  2022-05-13       Impact factor: 4.614

6.  Common variants in PCSK1 influence blood pressure and body mass index.

Authors:  Q Gu; M Yazdanpanah; M van Hoek; A Hofman; X Gao; F W M de Rooij; E J G Sijbrands
Journal:  J Hum Hypertens       Date:  2014-07-17       Impact factor: 3.012

7.  Vesicle-associated membrane protein-2 (VAMP2) mediates cAMP-stimulated renin release in mouse juxtaglomerular cells.

Authors:  Mariela Mendez; Kenneth W Gross; Sean T Glenn; Jeffrey L Garvin; Oscar A Carretero
Journal:  J Biol Chem       Date:  2011-06-27       Impact factor: 5.157

8.  Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors.

Authors:  Eduardo Pimenta; Suzanne Oparil
Journal:  Ther Clin Risk Manag       Date:  2009-06-22       Impact factor: 2.423

Review 9.  Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors.

Authors:  Eduardo Pimenta; Suzanne Oparil
Journal:  Vasc Health Risk Manag       Date:  2009

Review 10.  The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction.

Authors:  Paolo Verdecchia; Fabio Angeli; Giovanni Mazzotta; Giorgio Gentile; Gianpaolo Reboldi
Journal:  Vasc Health Risk Manag       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.